Intuitive Surgical Inc
NASDAQ:ISRG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (19.1), the stock would be worth $540.27 (15% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 16.6 | $470.99 |
0%
|
| 3-Year Average | 19.1 | $540.27 |
+15%
|
| 5-Year Average | 19.1 | $540.27 |
+15%
|
| Industry Average | 1.7 | $49.46 |
-89%
|
| Country Average | 2.4 | $69.04 |
-85%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$178.4B
|
/ |
Jan 2026
$10.1B
|
= |
|
|
$178.4B
|
/ |
Dec 2026
$11.7B
|
= |
|
|
$178.4B
|
/ |
Dec 2027
$13.4B
|
= |
|
|
$178.4B
|
/ |
Dec 2028
$15.3B
|
= |
|
|
$178.4B
|
/ |
Dec 2029
$16.7B
|
= |
|
|
$178.4B
|
/ |
Dec 2030
$18.7B
|
= |
|
|
$178.4B
|
/ |
Dec 2031
$19.5B
|
= |
|
|
$178.4B
|
/ |
Dec 2032
$21.3B
|
= |
|
|
$178.4B
|
/ |
Dec 2033
$23.2B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
167.2B USD | 16.6 | 58.6 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161.2B USD | 3.6 | 25.7 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.8B USD | 5 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.4B USD | 3 | 23.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.9B USD | 4.3 | 24.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 7.7 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.1B EUR | 1.7 | 19 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.8B USD | 10.7 | 43.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.8B USD | 2 | 24.3 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32.3B USD | 6 | 21.8 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
31.4B USD | 1.6 | 15.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Intuitive Surgical Inc
Glance View
In the rapidly evolving landscape of medical technology, Intuitive Surgical Inc. stands as a pioneer, revolutionizing the way surgeries are performed through its groundbreaking robotic systems. Founded in 1995, the company has set the benchmark for minimally invasive surgery with its flagship product, the da Vinci Surgical System. This sophisticated platform integrates advanced robotics, 3D visualization, and intuitive controls to enable surgeons to perform intricate procedures with precision and control that far surpass conventional methods. By enhancing the dexterity of the human hand and allowing for remarkably steady movements, the system reduces the physical strain on surgeons while improving patient outcomes in terms of reduced recovery time, minimized scarring, and lower risk of infection. Intuitive Surgical’s business model is both innovative and practical, capitalizing on a combination of product sales, ongoing service agreements, and instrument and accessory sales. Initially, hospitals and medical centers invest significantly in acquiring the da Vinci Systems, providing Intuitive with substantial capital inflows. However, the true genius of the company's revenue model lies in its ecosystem approach; ongoing revenue is generated through the sale of disposable instruments and components needed for each surgery. Additionally, the firm offers extensive maintenance and support services, ensuring that healthcare providers maximize their return on investment while maintaining optimal performance of their surgical systems. This balanced model creates a consistent and reliable income stream, enhancing the company's financial stability and enabling it to invest continually in research and development.